Non-alcoholic Steatohepatitis Biomarkers Market Size was valued at USD 0.12 Billion in 2023. The non-alcoholic steatohepatitis biomarkers market industry is projected to grow from USD 0.15 Billion in 2024 to USD 0.996 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 26.19% during the forecast period (2024 - 2032). Due to market drivers including the increased incidence of chronic liver disorders, which is anticipated to raise demand for non-invasive diagnostic methods for NASH detection, the non-alcoholic steatohepatitis (NASH) biomarkers market is expanding. Moreover, the introduction of cutting-edge diagnostic tests is fueling market expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The growing emphasis on non-invasive diagnostic methods is one major industry trend. Early and correct identification is essential for the management and treatment of NASH because it is a complex and progressing liver disease. Non-invasive biomarkers, such as blood-based testing and imaging methods, provide advantages over invasive liver biopsies, including less discomfort for patients, cheaper costs, and greater accessibility. Due to the demand for dependable and practical diagnostic methods, the discovery and application of non-invasive biomarkers for NASH diagnosis are gaining momentum. This pattern is anticipated to improve patient outcomes, simplify clinical studies, and fuel the expansion of the worldwide NASH biomarkers market CAGR.
The rising prevalence of NASH globally is one of the factors driving the market for NASH biomarkers. NASH is a liver condition marked by fat buildup in the liver, which causes inflammation and damage. The increasing prevalence of NASH is being attributed to the increased rates of obesity, sedentary lifestyles, and bad eating patterns. As a result, there is a requirement for efficient biomarkers that can correctly identify NASH, track the development of the condition, and evaluate therapy responsiveness. The need for more effective diagnostic techniques and the rising awareness of the condition are driving the demand for NASH biomarkers.
The development of the non-alcoholic steatohepatitis (NASH) biomarkers market will likely be significantly influenced by developments in the healthcare sector and research initiatives. Idiopathic pulmonary fibrosis (IPF) may one day be treated, and recently, a significant amount of research has been done to find those solutions. The development of NASH biomarkers is expected to experience a significant increase as a result of the rapid acceleration in the past ten years of the transition from NAFLD to NASH, which has become one of the most common chronic liver conditions, particularly in Western regions, including North America and Europe. Thus, driving the non-alcoholic steatohepatitis biomarkers market revenue.
The non-alcoholic steatohepatitis biomarkers market segmentation, based on type includes Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. The serum biomarkers segment dominated the market. The segment's dominance is related to serum biomarkers' success and widespread use as a diagnostic tool for NASH. Additionally, it has a competitive advantage when used to distinguish between primary steatosis and NASH. Apolipoprotein B, leptin, adiponectin, ghrelin, apolipoprotein A1, free fatty acids, and tumor necrosis factor-alpha are a few of the novel blood biomarkers that are anticipated to be released and are projected to accelerate market expansion.
Figure 1: Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The non-alcoholic steatohepatitis biomarkers market segmentation, based on distribution channel, includes Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. The pharmaceutical companies and CROs category generated the most income. The market is expected to expand as a result of the increased demand for non-invasive diagnostic techniques to identify chronic liver disease and the rising prevalence of liver ailments. Additionally, as a result of improved diagnostics, the market for treatments is expanding, which raises the need for pharmaceuticals and ultimately supports the expansion of the entire industry.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American non-alcoholic steatohepatitis biomarkers market area will dominate this market attributed to a number of variables, including the rising diagnosis rate and the early introduction of novel products in this area. There is a wealth of money available for biomarker research and development, supporting attempts to produce new medications and promoting business growth. Important market-driving variables include the rising availability of tests and the mobility of players within the U.S. market.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe non-alcoholic steatohepatitis biomarkers market accounts for the second-largest market share. This region is important for the discovery of NASH biomarkers because it has a strong healthcare infrastructure, cutting-edge diagnostic tools, and a high prevalence of NASH. Numerous significant pharmaceutical and biotechnology firms with operations in the area are engaged in the creation and marketing of NASH biomarkers. Further, the German non-alcoholic steatohepatitis biomarkers market held the largest market share, and the UK non-alcoholic steatohepatitis biomarkers market was the fastest growing market in the European region
The Asia-Pacific Non-alcoholic steatohepatitis biomarkers Market is expected to grow at the fastest CAGR from 2024 to 2032 because obesity is becoming more common, more people lead sedentary lives, and eating habits are changing. Additionally, there is a rising understanding of the early detection and management of NASH among patients and healthcare providers. Biomarker-based diagnostics are therefore becoming more and more in demand in this area. Moreover, China’s non-alcoholic steatohepatitis biomarkers market held the largest market share, and the Indian non-alcoholic steatohepatitis biomarkers market was the fastest growing market in the Asia-Pacific region.
Non-alcoholic Steatohepatitis Biomarkers Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the non-alcoholic steatohepatitis biomarkers market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, non-alcoholic steatohepatitis biomarkers industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the non-alcoholic steatohepatitis biomarkers industry to benefit clients and increase the market sector. In recent years, the non-alcoholic steatohepatitis biomarkers industry has offered some of the most significant advantages to market. Major players in the non-alcoholic steatohepatitis biomarkers market attempting to increase market demand by investing in research and development operations include Perspectum Diagnostics Ltd., Shenzhen New Industries Biomedical Engineering Co Ltd, One Way Liver SL, BioPredictive, Cisbio, Celerion, Enterome, Echosens, GENFIT, NGM Biopharmaceuticals, Laboratory Corporation of America Holdings, Pacific Biomarkers, Quest Diagnostics Ltd, Prometheus Laboratories Inc, Regulus Therapeutics Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Bristol-Myers Squibb, AstraZeneca and Pfizer Inc.
NGM Biopharmaceuticals Inc. (NGM Bio) is a clinical-stage biopharmaceutical business that creates a pipeline of biological medicines for the treatment of ophthalmic, immuno-oncological, retinal, and liver disorders, as well as cardio-metabolic and immuno-metabolic conditions. Multiple technologies are incorporated into the company's biologic platform to produce and screen monoclonal antibodies.
Through a network of laboratories and business-owned patient service centers, Quest Diagnostics Inc. (Quest Diagnostics) offers diagnostic information services to patients and physicians. It provides a variety of services, including as anatomic pathology, clinical trial testing, life insurer services, genetic testing, gene-based testing, and other specialized tests, as well as a range of medical information technology and diagnostic devices. Among others, Quest Diagnostics offers its services to hospitals, clinics, managed care organizations, other health insurance companies, laboratories, and governmental institutions.
Key Companies in the non-alcoholic steatohepatitis biomarkers market include
Non-alcoholic Steatohepatitis Biomarkers Industry Developments
April 2023:A ground-breaking imaging biomarker for evaluating NASH was introduced by BioGenomics Inc. The non-invasive imaging technology allows for the precise observation and measurement of liver fibrosis, inflammation, and fat, which is helpful for disease staging and therapy monitoring.
February 2023:The creation of a brand-new blood-based biomarker panel for the early diagnosis of NASH was successfully announced by Biopredictive Biotech. When detecting at-risk patients and distinguishing NASH from other liver disorders, the panel exhibits encouraging accuracy.
September 2021:To create a non-invasive composite biomarker for non-alcoholic steatohepatitis using feces samples, Second Genome and Virginia Commonwealth University worked together on study.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.12 Billion |
| Market Size 2024 | USD 0.15 Billion |
| Market Size 2032 | USD 0.996 Billion |
| Compound Annual Growth Rate (CAGR) | 26.19% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Perspectum Diagnostics Ltd., Shenzhen New Industries Biomedical Engineering Co Ltd, One Way Liver SL, BioPredictive, Cisbio, Celerion, Enterome, Echosens, GENFIT, NGM Biopharmaceuticals, Laboratory Corporation of America Holdings, Pacific Biomarkers, Quest Diagnostics Ltd, Prometheus Laboratories Inc, Regulus Therapeutics Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Bristol-Myers Squibb, AstraZeneca and Pfizer Inc |
| Key Market Opportunities | Developments in the healthcare sector and research initiatives |
| Key Market Dynamics | Growing emphasis on non-invasive diagnostic methods Rising prevalence of NASH globally |
Non Alcoholic Steatohepatitis Biomarkers Market Highlights:
Frequently Asked Questions (FAQ) :
The non-alcoholic steatohepatitis biomarkers market size was valued at USD 0.12 Billion in 2023.
The market is projected to grow at a CAGR of 26.19% during the forecast period, 2024-2032.
North America had the largest share in the market.
The key players in the market are Perspectum Diagnostics Ltd., Shenzhen New Industries Biomedical Engineering Co Ltd, One Way Liver SL, BioPredictive, Cisbio, Celerion, Enterome, Echosens, GENFIT, NGM Biopharmaceuticals, Laboratory Corporation of America Holdings, Pacific Biomarkers, Quest Diagnostics Ltd, Prometheus Laboratories Inc, Regulus Therapeutics Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Bristol-Myers Squibb, AstraZeneca and Pfizer Inc.
The serum biomarkers category dominated the market in 2023.
The pharmaceutical companies and CROs category had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
